On October 16, 2025, C4 Therapeutics, Inc. published data from its Phase 1 clinical trial of cemsidomide for treating relapsed/refractory multiple myeloma, and terminated a sales agreement after selling 3,769,483 shares for about $9.6 million in gross proceeds.